Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
HealthDay News — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in JAMA Surgery ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...
Scientists have discovered a naturally-occurring molecule that rivals the weight-loss effects of semaglutide-based GLP-1s like Ozempic in animals.
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...